Crizotinib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Crizotinib: From ALK-Positive Non-Small Cell Lung Cancer to Fibromatosis, Gingival
One-Sentence Summary
Crizotinib is a first-in-class ATP-competitive inhibitor of ALK, ROS1, and MET receptor tyrosine kinases, clinically established for the treatment of ALK- or ROS1-rearranged non-small cell lung cancer (NSCLC). The TxGNN model ranks Fibromatosis, Gingival as the highest-scoring new indication (score 99.81%), yet no clinical trials and no supporting literature exist for this specific prediction; mechanistic analysis in this evidence pack identifies the signal as a likely knowledge graph topological artefact rather than a genuine therapeutic opportunity. Based on the totality of evidence in this pack, the recommended decision for this top-ranked indication is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC) |
| Predicted New Indication | Fibromatosis, Gingival |
| TxGNN Prediction Score | 99.81% |
| Evidence Level | L5 |
| EU Market Status | No EMA authorizations recorded in dataset |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on published information from the supporting literature, Crizotinib (Xalkori®) is an oral small-molecule inhibitor that competitively blocks three oncogenic receptor tyrosine kinases: ALK (anaplastic lymphoma kinase), ROS1 (c-ros oncogene 1), and MET (hepatocyte growth factor receptor). Its efficacy has been robustly demonstrated in ALK-rearranged and ROS1-rearranged advanced NSCLC, with regulatory approval in multiple major jurisdictions. Relevant peer-reviewed reviews (PMID 24756793, 30069759) summarise its approved mechanism and clinical profile.
Fibromatosis, gingival is a rare condition characterised by benign, progressive overgrowth of gingival connective tissue. The primary genetic aetiologies involve mutations in SOS1 or EPAS1, while drug-induced forms are driven by cyclosporine or phenytoin use. None of these pathways have a known intersection with ALK, ROS1, or MET signalling — the three kinases that Crizotinib targets.
The TxGNN model’s high prediction score of 99.81% is most plausibly explained by shared topological nodes in the knowledge graph — specifically, nodes associated with fibroblast proliferation that appear in proximity to both gingival fibromatosis and cancer-related stromal processes. This constitutes structural noise rather than a true mechanistic link. The complete absence of any clinical trial registration or peer-reviewed literature further confirms that this prediction does not represent a viable repurposing hypothesis at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered for Fibromatosis, Gingival.
Literature Evidence
Currently no related literature available for Fibromatosis, Gingival.
Cytotoxicity
Crizotinib is an antineoplastic agent approved for malignant NSCLC with specific oncogenic driver mutations.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy — ALK/ROS1/MET tyrosine kinase inhibitor (first-generation) |
| Myelosuppression Risk | Low to moderate; neutropenia reported but less severe than conventional cytotoxics; see PMID 41617059 for mechanism review |
| Emetogenicity Classification | Low to moderate; nausea and vomiting are among the most common adverse effects, typically manageable with anti-emetic support |
| Monitoring Items | Liver function tests (ALT, AST, total bilirubin), CBC with differential, 12-lead ECG for QTc prolongation, chest imaging for interstitial lung disease (ILD), ophthalmological assessment |
| Handling Protection | Standard cytotoxic drug handling precautions apply; personnel should follow institutional guidelines for oral antineoplastic agents |
Safety Considerations
Please refer to the SmPC for safety information.
Note: PMID 41617059 (2026 review) specifically addresses crizotinib-induced multisystem toxicities including hepatotoxicity, cardiotoxicity (QT prolongation, bradycardia — see also PMID 29717400), and interstitial lung disease. PMID 26898609 documents a case of fatal fulminant liver failure after 24 days of therapy. These signals warrant careful monitoring protocols in any future use.
Conclusion and Next Steps
Decision: Hold
Rationale: The highest-ranked TxGNN prediction for Crizotinib — Fibromatosis, Gingival — carries no clinical trial evidence, no supporting literature, and lacks any plausible mechanistic connection between ALK/ROS1/MET inhibition and gingival fibroblast overgrowth pathways (SOS1/EPAS1/drug-induced). The high model score is consistent with knowledge graph structural noise and does not constitute a research hypothesis.
To proceed with any Crizotinib repurposing programme, the following is needed:
- Redirect to higher-evidence indications in this evidence pack: Lung Germ Cell Tumor (Rank 6, L3, S1 — 4 clinical trials including NCI MATCH Phase 2 and a Phase 1b directly in ALK+ tumours) and Lung Hilum Carcinoma (Rank 4, L4, S1 — 2 case reports with ALK+ and ROS1+ molecular confirmation) are substantively more promising
- Mandatory molecular pre-selection: Any repurposing hypothesis for Crizotinib must be gated on ALK rearrangement, ROS1 fusion, or MET exon 14 skipping status in the target tumour type
- Complete MOA data: Retrieve full pharmacological profile from DrugBank API (gap DG002)
- Safety pre-screening: Obtain SmPC warnings and contraindications via TFDA/EMA official sources (gap DG001, currently blocking S1 safety evaluation)
- DDI profiling: No drug-drug interaction data was retrievable; formal DDI assessment required before any clinical pathway planning
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.